Immunomedics to Present Updated Phase II Results From Antibody-Drug Conjugate Programs at 2014 ASCO

        Print
| Source: Immunomedics, Inc.

MORRIS PLAINS, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), today announced that five posters on its product candidates will be presented at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) scheduled for May 30 – June 3, 2014 at the McCormick Place Convention Center in Chicago, Illinois.

Three of the 5 presentations will be on our antibody-drug conjugate (ADC) programs for solid cancers, including IMMU-132, which will be featured in a Poster Highlights Session. Presented at a separate Poster Highlights Session will be our radiolabeled antibody for advanced pancreatic cancer, 90Y-clivatuzumab tetraxetan, which is in a Phase III registration study in patients with relapsed pancreatic cancer. A preclinical study on a T-cell redirecting bispecific antibody targeting pancreatic and gastric cancers will also be reported. Details of the presentations are listed below (all times are in Central Time):

Sunday, June 1, 2014

  • Feasibility and results of a randomized phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies (Picozzi, et al.)
    Poster Highlights Session: Gastrointestinal (Noncolorectal) Cancer
    Abstract #4026, Poster Board #45
    8:00 a.m. - 11:00 a.m.
    E354b
     
  • Effect of interferon-α on redirected Τ-cell killing of pancreatic and gastric cancers (Goldenberg, et al.)
    General Poster Session: Developmental Therapeutics – Immunotherapy
    Abstract #3056, Poster Board #123
    8:00 a.m. - 11:45 a.m.
    S Hall A2
     
  • Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study (Dotan, et al.)
    General Poster Session: Developmental Therapeutics – Immunotherapy
    Abstract #3106, Poster Board #173
    8:00 a.m. - 11:45 a.m.
    S Hall A2
     
  • Characterization of an anti-ΤROP-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers (Goldenberg, et al.)
    General Poster Session: Developmental Therapeutics – Immunotherapy
    Abstract #3107, Poster Board #174
    8:00 a.m. - 11:45 a.m.
    S Hall A2

Monday, June 2, 2014

  • IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting ΤROP-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results (Starodub, et al.)
    Poster Highlights Session: Developmental Therapeutics - Immunotherapy
    Abstract #3032, Poster Board #24
    1:15 p.m. - 4:15 p.m.
    S405

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), who has worldwide rights in non-cancer indications to Immunomedics' Phase III product candidate, epratuzumab. UCB expects Phase III data in systemic lupus erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with outside cancer study groups. Immunomedics' most advanced wholly owned candidate is 90Y-clivatuzumab tetraxetan, which is in an ongoing Phase III registration trial in patients with pancreatic cancer. Immunomedics' portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicity effects that typically occur when these chemotherapeutic agents are dosed alone. Immunomedics' most advanced ADCs are IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies which have application as T-cell redirecting immunotherapies targeting cancers and infectious diseases as well as next-generation therapies in cancer and autoimmune disease. Immunomedics creates these bispecific antibodies using its patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 248 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedics' strength in intellectual property has resulted in the top-4 ranking in the January 2014 Patent Board scorecard in the Biotechnology industry. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. Chau Cheng
Senior Director, Investor Relations & Grant Management
(973) 605-8200, extension 123